Study summary · research use only
[Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this human study, the authors examined the thymomimetic peptide Vilon on immune status and coagulation hemostasis in elderly patients with type I diabetes mellitus. The abstract reports that adding Vilon to complex therapy was associated with what the authors describe as optimized coagulation hemostasis, manifested as increased natural anticoagulants (antithrombin III and protein C) and stimulation of fibrinolysis. In most cases Vilon was said to reduce the insulin dose needed for stabilization of carbohydrate metabolism. The content of T-helpers and T-dependent and non-T-dependent NK cells was reduced, and levels of active T-lymphocytes, B-lymphocytes, and IgA were reported as normalized, which the authors interpret as a stabilizing action of Vilon on the immune system and hemostasis. No numerical figures were provided.
Abstract
Improving the status of elderly patients with diabetes mellitus is an important issue of gerontology and geriatrics. This work was aimed at the study of the effect of thymomimetic Vilon on the immune status and coagulation hemostasis in elderly patients with type I diabetes mellitus. It was found that the administration of Vilon as an addition to the complex therapy for this cohort of patients resulted in optimization of coagulation hemostasis, which was manifested in the increased content of natural anticoagulants: antithrombin III and protein C, as well as in the stimulation of fibrinolysis. In most cases Vilon reduced the dose of insulin necessary for the stabilization of carbohydrate metabolism. The content of T-helpers, T-dependent and non-T-dependent NK cells was reduced, and the level of active T-lymphocytes, B-lymphocytes and IgA was normalized, which points out the stabilizing effect of Vilon on the immune system and hemostasis.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.